作者: E. Bonafonte Márquez , D. De Ortueta , S. Bonafonte Royo , Pedro A. Martínez-Carpio
DOI: 10.3109/15569527.2010.498398
关键词:
摘要: Agonist and antagonist drugs acting on epidermal growth factor receptor (EGFR) signaling are emerging as a new possibility for pharmaceutical study clinical manipulation of some skin corneal disorders. EGFR activation appears to be effective in reducing the time reepithelialization after wound healing, with potential uses penetrating keratoplasty, refractive surgery, alkali burns, diabetic keratopathy, keratopathy following chemotherapy, cornea transplantation, dry eye. Most studies show therapeutic advantages human recombinant (hrEGF) eye drops without showing adverse effects. In contrast, inhibition delays epithelial cell proliferation stratification during regeneration.The aim this review is summarize most seminal discoveries recent advances so clarify role system physiology pharmacology. Epidermal could first-choice treatment promoting regener...